Why the study?
Does trial eligibility status affect in-hospital mortality in STEMI patients undergoing primary angioplasty?
Does trial eligibility status affect in-hospital mortality in STEMI patients undergoing primary angioplasty?
Answers are grounded in this paper and cite their sources.
Nearly 50% of STEMI patients undergoing primary angioplasty are ineligible for clinical trials and have significantly higher in-hospital mortality, suggesting trial results underestimate real-world mortality rates.
We determined acute outcome in 148 consecutive patients with ST segment elevation myocardial infarction undergoing angioplasty including 72 patients (48.7%) considered ineligible for primary angioplasty trials. Overall, in-hospital mortality for acute infarct angioplasty was 12%, with fivefold higher mortality in the trial-ineligible group (21% vs. 4%, P = 0.003). Thus, primary angioplasty trials continue to exclude nearly 50% of acute infarction patients and reported mortality rates of primary angioplasty trials are likely to be significantly lower than the unselected in-hospital mortality rates. Cathet. Cardiovasc. Intervent. 49:237-243, 2000.
No takes yet. Share an insight, caveat, or question.
Dauerman et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: